# Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

> **NCT02247401** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 160 (actual)

## Conditions studied

- HCV
- Hepatitis C Infection
- Genotype 4

## Interventions

- **DRUG:** 2 DAA
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02247401
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-04
- **Primary completion:** 2016-08-01
- **Final completion:** 2016-08-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247401, "Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02247401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*